Role of heat stable fraction of alkaline phosphatase as an adjunct to CA 125 in monitoring patients of epithelial ovarian carcinoma

Indian Journal of Clinical Biochemistry

Volumn 20, Issue 2, 2005, Pages 43-47

  Nigam, P K ^a,b   Jain, A ^a   Goyal, P ^a   Chitra, R ^a  

^a LADY HARDINGE MEDICAL COLLEGE   (India)

^b Dr Lal Path Labs   (India)

Author keywords

CA 125; Heat stable fraction of ALP; Ovarian cancer; PLAP; Tumour marker

Indexed keywords

ALKALINE PHOSPHATASE; CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TUMOR MARKER;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; OVARY CARCINOMA; PATIENT MONITORING; PREOPERATIVE EVALUATION; SENSITIVITY AND SPECIFICITY; THERMOSTABILITY;

EID: 24044438193     PISSN: 09701915     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02867399     Document Type: Article

References (16)

1. Haije, W.G. (1982) Biochemical markers in ovarian cancer: possibilities and limitations. Ann. Clin. Biochem. 19, 258-262.
2. Tammela, J. and Lele, S. (2004) New modalities in detection of recurrent ovarian cancer. Curr. Opin. Obstet. Gynecol. 16, 5-9
3. Thakur, V., Anand, A.K., Mukherjee, U. and Ghosh, D. (2003) Determination of cancer antigen 125 in ovarian carcinoma. Indian J. Clin. Biochem. 18, 27-33.
4. Nouwen, E.J., Rollet, D.E., Schelstraete, J.B., et al. (1985) Human placental alkaline phosphatase in benign and malignant ovarian neoplasia. Cancer Res. 45, 3244-3247.
5. FIGO Cancer Committee. (1986) Stage grouping for primary carcinoma of ovary. Gynecol. Oncol. 25, 383-385.
6. Serov, S.F., Scully, R.E. and Sorbin, L.H. (1973) Histological typing of ovarian tumours In: International Histological Classification of Tumours Geneva, Switzerland: World Health Organization. 17-18.
7. Fishman, W.H., Bardawil, W.A., Habibm, H.G., Anstiss, C.L. and Green, S. (1962) The placental isoenzyme of alkaline phosphatase in sera of normal pregnancy. Am. J. Clin. Pathol. 57, 65.
8. Hausamen, T.U., Helger, R., Rick, W. and Gross, W. (1967) Optimal conditions for the determination of serum alkaline phosphatase by a new kinetic method. Clin. Chim. Acta. 15, 241-245.
9. Young, R.C., Perez, C.A. and Hoskins, W.J. (1993) Cancer of the ovary. Cancer Principles and Practice of oncology. Philadelphia: J B Lippincott Company 5, 1226-1263.
10. Joly, D.J., Lilienfeld, A.M., Diamond, E.L., Bross, I.D. (1974) An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am. J. Epidemiol. 99, 190-209.
11. Beral, V., Fraser, P. and Chilvers, C. (1978) Does pregnancy protect against ovarian cancer? Lancet 1, 1083-1087.
12. Silveston, A., Tobias, U.S. and Benjamin, E. (1997) Gynecologic oncology. Mosby Wolfe U.K., 1-8.
13. Nozawa, S., Udagawa, Y., Ohkura, H., et al. (1989) Serum placental alkaline phosphatase (PLAP) in gynaecologic malignancies with special reference to the combination of PLAP and CA54/ 61 assay. Clin. Chem. Acta. 186, 275-284.
14. Ward, B.G., Cruickshank, D.J., Tucker, D.F. and Love, S. (1987) Independent expression in serum of three tumour-associated antigens: CA125, placental alkaline phosphatase and HMFG2 in ovarian carcinoma. Br. J. Obstet. Gynaecol. 94, 696-698.
15. Bast, R.C., Knauf, S., Epenetos, A., et al. (1991) Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 68, 1758-1763.
16. Vergote, I.B., Bormer, O.P. and Abeler, V.M. (1987) Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am. J. Obstet. Gynecol. 157, 88-92.